All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Chanrx Corp. moved a step closer to the goal line for lead candidate vanoxerine (GBR-12909), reporting Phase IIb data at the American Heart Association (AHA) 2013 Scientific Sessions suggesting the drug’s efficacy approached that of direct current (DC) cardioversion for patients with atrial fibrillation.